Phacoemulsification in Acute Congestive Glaucoma

Sponsor
Hany Mahmoud (Other)
Overall Status
Recruiting
CT.gov ID
NCT05289453
Collaborator
(none)
25
1
1
3.9
6.3

Study Details

Study Description

Brief Summary

Acute primary angle closure (APAC) is usually caused by an abrupt closure of the trabecular meshwork in the anterior chamber angle that leads to a sudden rise in intraocular pressure (IOP). APAC is a subgroup of angle closure disease characterised by a sudden onset of headache, blurred vision, seeing halos around lights, corneal oedema, mid-dilated pupil, eye pain and redness. Asian also has a much higher incident rate of APAC compare to the Caucasian population - with the crude incidence rate of 12.2 and 10.4 per 100,000 people per year in the above 30-year-old population of Singapore and Hong Kong, respectively . This is higher than the average incidence rate of 3.9-4.1 cases per 100,000 people per year in the European regions .

In APAC, both LPI and primary lens extraction by phacoemulsification and intraocular lens implant (phaco/IOL) were demonstrated to be effective to control IOP elevation. The latter has been shown to be the more effective treatment than LPI for IOP reduction at the early and mid-term IOP control. Together with the advancement of phaco/IOL technique, primary lens extraction is the more popular choice of treatment nowadays. However, operating on an eye with early aborted APAC is technically challenging and may increase the risk of complications because of the presence of corneal oedema, inflammation, shallow anterior chamber, floppy iris and unstable lens. Furthermore, "the best time window" for performing lens extraction after an APAC attack remains uncertain. The long-term results (e.g. more than 5 years) of early lens extraction compared to the conventional LPI are also unknown. In this study, we summarise the approach of treating APAC at the initial acute stage and review the studies that consider IOP control in the mid and long term. We would also touch on the role of goniosynechialysis, trabeculectomy and endoscopic cyclophotocoagulation in treating APAC, as well as considering the economic aspect of treatment.

Aim of the study: to evaluate the safety and efficacy of phacoemulsificatiojn in cases of acute congestive glaucoma

Condition or Disease Intervention/Treatment Phase
  • Procedure: lens extraction by phacoemulsification
N/A

Study Design

Study Type:
Interventional
Anticipated Enrollment :
25 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Phacoemulsification in Acute Congestive Glaucoma
Actual Study Start Date :
Feb 20, 2022
Anticipated Primary Completion Date :
Jun 20, 2022
Anticipated Study Completion Date :
Jun 20, 2022

Arms and Interventions

Arm Intervention/Treatment
Experimental: study group

patients wit acute congestive glaucoma and treated bt lens extraction by phacoemulsification after IOP control

Procedure: lens extraction by phacoemulsification
lens extraction by phacoemulsification

Outcome Measures

Primary Outcome Measures

  1. iop control [3 months follow-up]

    iop will be assessed by applination tonometry and the values will be recorded, the success is defined by normal iop values during follow up period (3 months)

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • patients with acute congestive glaucoma
Exclusion Criteria:
  • people under 18 years

Contacts and Locations

Locations

Site City State Country Postal Code
1 Hany Mahmoud Sohag Egypt

Sponsors and Collaborators

  • Hany Mahmoud

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Hany Mahmoud, principal investigator, Sohag University
ClinicalTrials.gov Identifier:
NCT05289453
Other Study ID Numbers:
  • soh-med-22-02-29
First Posted:
Mar 21, 2022
Last Update Posted:
Mar 21, 2022
Last Verified:
Mar 1, 2022
Individual Participant Data (IPD) Sharing Statement:
Yes
Plan to Share IPD:
Yes
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Mar 21, 2022